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During the last 2 decades, human and animals studies have clearly documented the crucial 
role of inflammation in the development and complications of atherosclerosis 
1
. Both innate 
and adaptive immunity are involved in this process. The first evidence that suggested a role of 
adaptive immunity in atherosclerosis was the widespread detection of the major 
histocompatibility class II in human atherosclerotic plaques, and the presence of a large 
amounts of CD3
+
 lymphocytes in human and mouse atherosclerotic lesions. Most of T cells in 
mouse and human atherosclerotic plaques are CD4
+
 T-helper(Th) cells expressing the αβ T-
cell antigen receptor (TCR).Among CD4
+
T cells, Th1 cells have been shown to exert 
proatherogenic effects, whereas regulatory T cells (Tregs) display atheroprotective properties. 
The role of Th2 and Th17 cells is still debated
1
. Helper T cell subsets are defined by the 
production of cytokines and/or the expression of characteristic lineage-defining transcription 
factors. Th1 cells are generated upon priming in the presence of IL-12 that promotes the 
expression of the transcriptionfactor T-bet and stimulatesthe production of the Th1 
prototypical cytokine IFN-γ2. Tregshave a central role in the dominant control of 
immunologicaltolerance and maintenance of immune homeostasis. They were first identified 
in miceand later in humans
3
. The transcription factor FoxP3 is essential for the generation and 
the functions ofTregs
4
. FoxP3 deficiency leads to a multi-organ autoimmune disease as can be 
observed in the „scurfy‟ mouse and in human immune dysregulation, polyendocrinopathy, 
enteropathy X–linked syndrome (IPEX) patients5. Natural or thymic FoxP3+ Tregs acquire 
regulatory lineage commitment already upon maturation in the thymus 
3
, whereas adaptive or 
peripheral Foxp3
+
 Tregs can be induced from mature CD4
+
Thcells in the periphery under the 
influence of different stimulations, especially TGF-6. Other subsets of Tregs that do not 
express FoxP3 have been described. Tr-1 cells are characterized by the production of large 
amounts of IL-10, a potent anti-inflammatory and anti-atherosclerotic cytokine, and IL-10-
dependent suppression of T cell responses 
7
. In atherosclerosis, Tregs and Tr-1 cells exert 
protective effects. Significant acceleration of atherosclerosis has been observed in mice with 
reduced Treg cell numbers, as obtained by invalidation of CD80/86, CD28, ICOS or after 
treatment with CD25-depleting antibodies 
8 ,9
. Other approaches for Treg cell depletion, 
including antisense-induced Treg cell apoptosis, vaccination of mice against FoxP3, or use of 
mice expressing the diphtheria toxin receptor under control of the FoxP3 promoter
10
, all 
concluded to increased vascular inflammation and atherosclerosis in the absence of Tregs. In 
contrast, adoptive transfer of CD4
+
CD25
high
 Treg cells 
8
or IL-10 producing Tr-1 cells 
11
reduced atherosclerotic lesion development in Apoe
-/-
 mice.  
 3 
Th cells express a « lineage-specific » transcription factor that controls their generation, 
effector cytokine production, phenotype and function, and prevents the differentiation to an 
alternative lineage. Nevertheless, it has become increasingly clear that cells belonging toa 
specific Th lineage are notexclusively terminally differentiated cells, but that some maintain a 
certain degree of plasticity. Mature CD4
+
 T cells can acquire characteristicsof alternative 
lineages upon antigen restimulation
12
. For example, IL-12can induce IL-10 production by Th1 
cells and IFN-γ/IL-10 co-producing T cells with regulatory functions have been reported in 
peripheral blood of healthy donors
13
. IFN-γ/IL-10 co-producing T cells could also be 
generated after stimulation of Th17 cells in the presence of IL-12 or IL-27 
14
. Recent findings 
suggest that FoxP3
+
Tregsalso show functional and phenotypic plasticity, beingable to secrete 
proinflammatory cytokines. For instance, Tregs expressing the T-bet and the Th1-associated 
chemokine receptor CXCR3 canswitch to a Th1 program and accumulate at sites of Th1 
inflammatory responses
15
. 
In this issue of Circulation Research, Li et al. report for the first time data showingthat more 
than40%of CD4
+
 T cellsin atherosclerotic aorta of Apoe-/-mice under high fat dietexpress 
CCR5and exhibit a unique repertoire of molecular and cell surface markers, including 
positivity for FoxP3,T-bet, and IFN-γ, but are CD25negative.These so-called « CCR5Teff » 
cells use CCR5 and its ligand CCL5 to home to the aorta and interact with CD11c
+
antigen 
presenting cells there. 
Interestingly, it is now well accepted that a transcription factor is not the « sole » requisite 
signature that determines a specific Th lineage. Foxp3 transduction by itself is not sufficient 
to completely recapitulate the Treg-transcriptional profile. This conclusion issupported by 
studies employing Tregs with non-functional Foxp3, which demonstrated that not all Foxp3
+
 
T cells are functional Tregs, and that part of the Treg signature can be induced in the absence 
of FoxP3
16
. In their study, Li et al. have shown that Foxp3
+
CCR5Teff were able to 
significantly reduce IFN-γ, IL-4, IL-13, Il-17A production by effector T cells,but were unable 
to suppress effector T cell proliferation.This might be accounted by theinability of CCR5Teff 
to suppress IL-2 secretion. As the proliferation of FoxP3
+
CCR5Teff cells themselves in the 
absence of effector T cells was not reported, it is difficult to classifythis vascular-located T 
cell population as true effector T cells that shouldproliferate in response to coated anti-CD3 or 
when co-cultured with mature antigen-presenting cells, whereas regulatory T cellsshould not. 
IL-2 is required to induce CD25
high
Treg cell proliferation in vitro. So-called FoxP3
+
CCR5 
Teff cells displaysome features of previously described Th1-like regulatory population that 
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co-expresses FoxP3, T-bet andIFN-γ. In the context of airway hyper-reactivity, it has been 
shown that T-bet
+
FoxP-3
+
 T cells induced by CD8+ dendritic cells canproduce both IL-10 
and IFN-γ 17. In the intestine, the conversion of FoxP3+Tregs into FoxP3+IFN-γ+ T cells, 
requiring IL-12 production by antigen-presenting cells, have also been described 
18
. However, 
in both studies the so-called “Th1-like Tregs” showed strong suppressive functions. They 
blocked effector T cell expansion and protected against organ specific inflammation. In the 
study by Li et al., the adoptive transfer of FoxP3
+
CCR5Teff cells into Ccr5
-/-
Apoe
-/-
micewas 
not protective, and waseven able to accelerate atherosclerosis to the same extentas 
“conventional” effector T cells.Therefore,in vitro and in vivo experiments rule out the 
possibility that FoxP3
+
CCR5Teff cells are Th1-like Tregs, and suggest thatthese cellsdisplay 
an effector T cell phenotype. This was supported by comprehensive transcriptome 
analysis.Effector T cell population expressing FoxP3 had never been described in mouse 
before, but had been previously reported in activated human T cells with unstable expression 
of FoxP3, whichdid notacquire suppressive function
19
.Li et al. clearly documentedthat FoxP3 
expression was very low in CCR5Teff cells, 5-6 fold lower thanin CD4
+
CD25
high
Tregs. In 
human, Miyara et al. characterized Treg cellsubsets according to theirFoxP3 expression
20
. 
They identified 3 different populations: CD45RA
+
FoxP3
low
 resting Treg cells, 
CD45RA
−
FoxP3
high
 activated Treg cells, and cytokine-secreting CD45RA
−
FoxP3
low
 non-Treg 
cells. Interestingly, the latter population had the same secretive and functional profileas the 
mouse CCR5Teff identified by Li et al. They both produced IL-2, IFN-γ and displayed no 
suppressive functions. 
Li et al. alsoexplored the role ofCCR5 onCD4
+
 T cells trafficking.Several studies have 
previously reported the pro-atherogenic role of CCR5, but most focused on monocytes. 
Pharmacological inhibition
21
or genetic invalidation ofCCR5significantly reduced 
monocytosis and atherosclerosis. CCR5 blocking prevented macrophage infiltration in the 
lesions and to a lower extent T cell infiltration.Li et al. reported that in vitro, pharmacological 
or genetic blocking of the CCL5-CCR5pathway in T cellsreduced their homing into explanted 
aorta, butin vivo evidence for specific migratory and pro-atherogenic properties of the newly 
discoveredCCR5
+
Teff cell populationwouldhave been more striking.They showed that the 
adoptive transfer of CCR5Teffcells in Ccr5
-/-
Apoe
-/-
miceaccelerated atherosclerosis. Yet, the 
same effect was observed following the adoptive transfer of  “conventional” effector T cells 
that expressed CCR5 at amuch lower level. It would have been of great interest to see whether 
thenumber of CCR5
+
Teff cells that accumulatedin the vascular wall was higher than that 
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of“conventional” effector T cells, which would strongly argue in favor ofa powerfulmigratory 
propertyof CCR5
+
Teff into atherosclerotic lesions. Finally,interestingly,CCR5
+
Teff cells were 
detected in the aorta and the draining lymph nodes, but not in the spleen, suggesting that their 
mature phenotype was acquired locally. Further studies are required todetermine the specific 
stimulatory pathway, antigen-dependent or antigen-independent,whichwas involved in CCR5 
expression on CCR5
+
 Teff cells. 
Collectively, knowledge gained from the present study by Li et al. about CCR5 as the major 
homing receptor for CD4
+
 T cells into atherosclerostic lesions will help to develop optimal 
therapies that either undermine pro-atherosclerotic effector T cells, or enhance the 
development ofstable and anti-atherogenic Tregs for immunotherapy. 
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Figure Legend 
Almost all of the CCR5+ T cells in aortas from Apoe-/-mice coexpress IFN-γ, T-bet and low 
level of FoxP3. These« CCR5Teff » cells are concentrated in the aorta, with some making 
their way to the para-aortic lymph nodes. They produce high levels of IFN-γ, TNFα, IL-10 
and IL-2, reducethe secretion of IFNγ, IL-4, IL-13, IL-6 and IL17A (but not IL-2 or IL-5), 
by effector CD4+CD25-T cells, but do not suppress the proliferation of the latter. Natural 
CD4+CD25hiFoxP3+Tregsinhibit effector Tcell proliferation and cytokine secretion. 
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